GALE : Analysis & Opinions

  1. Galena Biopharma: Clinical Programs Remain on Track and Valuation ...

    February 11, 2013
    Galena Biopharma: Clinical Programs Remain on Track and Valuation is Attractive By Grant Zeng, CFA Balance Sheet Boosted ...
  2. SPA for Aeterna Zentaris Candidate - Analyst Blog

    January 2, 2013
    Aeterna Zentaris Inc. (AEZS) recently announced that its oncology candidate, AEZS-108 (doxorubicin peptide conjugate) will ...
Trading Center